Pharma

Your Article Summary

See Latest Articles

UCB"s Cimzia, the Only Pegylated Anti-tnf, Approved in Europe
Enzon Pharmaceuticals, 10/07/09

Enzon Pharmaceuticals, Inc. announced that the European Commission has approved Cimzia, for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia, is a PEGylated anti–TNFa. The product is currently being developed by UCB and was approved in the US in May 2009. Cimzia is one of several products which utilize Enzon’s PEGylation technology, including Oncaspar, Adagen, PEGINTRON, Macugen, and Pegasys.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09

Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09

See All of Medical Devices/Products